Results 11 to 20 of about 1,343 (129)

Effect of Rabeprazole and Rebamipide in the Treatment of Upper Gastrointestinal Hemorrhage Associated with Dual Antiplatelet Therapy in Elderly Patients with Coronary Heart Disease

Clinical and Applied Thrombosis/Hemostasis, 2022
To investigate the therapeutic effect of rabeprazole and rebamipide on patient age over 60 with dual antiplatelet therapy (DAPT)–related upper gastrointestinal hemorrhage following percutaneous coronary intervention (PCI).
Rong-Jie Jia MD, Xiao-Peng Wang MM, Zhen-Hua Zhang MM, Hai-Hong Cui MD, Rui Qin MM, Da-Yong Du MM, Yang Liu MD   +6 more
doaj   +1 more source

Efficacy and safety of 1% and 2% rebamipide clear solution in dry eye disease: a multicenter randomized trial

BMC Ophthalmology, 2023
Background To evaluate the efficacy of 1% and 2% rebamipide clear solution in the treatment of dry eye disease (DED). Methods Two hundred twenty patients with DED were randomly assigned to one of three groups: the 1% rebamipide, 2% rebamipide, or placebo
Youngsub Eom, So Hyang Chung, Tae-Young Chung, Jae Yong Kim, Chul Young Choi, Kyung Chul Yoon, Byung Yi Ko, Hong Kyun Kim, Mee Kum Kim, Hyung Keun Lee, Jong Suk Song, Joon Young Hyon, Kyoung Yul Seo, Jong Soo Lee, Hyo Myung Kim   +14 more
doaj   +1 more source

Enhancement of the Solubility and Dissolution Rate of Rebamipide by Using Solid Dispersion Technique (Part I)

Iraqi Journal of Pharmaceutical Sciences, 2018
Solid dispersion is an attractive tool of pharmaceutical technology used to improve the physical properties of drugs. Among these properties is to enhance the solubility of the drugs.
Muna Y. Ismail, Mowafaq M. Ghareeb
doaj   +1 more source

A Phase 2, Multi-Center, Randomized, Double-Blind, Parallel-Group Trial to Evaluate the Efficacy and Safety of CKD-495 in Patients With Acute and Chronic Gastritis. [PDF]

Can J Gastroenterol Hepatol
CKD‐495 is a newly developed drug extracted from Cinnamomum cassia Presl. This phase II study assessed the clinical benefits of CKD‐495 in the treatment of acute and chronic gastritis. This study randomly assigned 250 patients with endoscopically‐proven gastric mucosal erosion to five groups.
Park SH, Lee OY, Lee YC, Park KS, Park JJ, Park MI, Song GA, Lee DH, Jung H, Kim SK, Kim TN, Choi SC, Jee SR, Rew JS, Lee ST, Choi EK, Baik GH, Park SJ.   +17 more
europepmc   +2 more sources

Refractory Cervical Necrotizing Fasciitis Successfully Controlled by Submandibular Gland Excision: A Case Report. [PDF]

Clin Case Rep
ABSTRACT Persistent cervical necrotizing fasciitis may indicate an unrecognized infectious reservoir. In refractory cases, excision of a suspected salivary gland may be required to achieve definitive infection control when repeated debridement fails.
Makihara H, Kitajima S, Maeda S, Mizuno S.   +3 more
europepmc   +2 more sources

A multicenter, randomized, double-blind, placebo-controlled trial of high-dose rebamipide treatment for low-dose aspirin-induced moderate-to-severe small intestinal damage. [PDF]

PLoS ONE, 2015
Low-dose aspirin (LDA) frequently causes small bowel injury. While some drugs have been reported to be effective in treating LDA-induced small intestinal damage, most studies did not exclude patients with mild damage thought to be clinically ...
Toshio Watanabe, Toshihisa Takeuchi, Osamu Handa, Yasuhisa Sakata, Tetsuya Tanigawa, Masatsugu Shiba, Yuji Naito, Kazuhide Higuchi, Kazuma Fujimoto, Toshikazu Yoshikawa, Tetsuo Arakawa   +10 more
doaj   +1 more source

Rebamipide ameliorates indomethacin-induced small intestinal damage and proton pump inhibitor-induced exacerbation of this damage by modulation of small intestinal microbiota.

PLoS ONE, 2021
Non-steroidal anti-inflammatory drugs (NSAIDs) induce small intestinal damage. It has been reported that rebamipide, a mucoprotective drug, exerts a protective effect against NSAID-induced small intestinal damage; however, the underlying mechanism ...
Tetsuya Tanigawa, Toshio Watanabe, Akira Higashimori, Sunao Shimada, Hiroyuki Kitamura, Takuya Kuzumoto, Yuji Nadatani, Koji Otani, Shusei Fukunaga, Shuhei Hosomi, Fumio Tanaka, Noriko Kamata, Yasuaki Nagami, Koichi Taira, Masatsugu Shiba, Wataru Suda, Masahira Hattori, Yasuhiro Fujiwara   +17 more
doaj   +1 more source

Efficacy and safety of rebamipide liquid for chemoradiotherapy-induced oral mucositis in patients with head and neck cancer: a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II study

BMC Cancer, 2017
Background Recent preclinical and phase I studies have reported that rebamipide decreased the severity of chemoradiotherapy-induced oral mucositis in patients with oral cancer.
T. Yokota, T. Ogawa, S. Takahashi, K. Okami, T. Fujii, K. Tanaka, S. Iwae, I. Ota, T. Ueda, N. Monden, K. Matsuura, H. Kojima, S. Ueda, K. Sasaki, Y. Fujimoto, Y. Hasegawa, T. Beppu, H. Nishimori, S. Hirano, Y. Naka, Y. Matsushima, M. Fujii, M. Tahara   +22 more
doaj   +1 more source

Rebamipide delivered by brushite cement enhances osteoblast and macrophage proliferation. [PDF]

PLoS ONE, 2015
Many of the bioactive agents capable of stimulating osseous regeneration, such as bone morphogenetic protein-2 (BMP-2) or prostaglandin E2 (PGE2), are limited by rapid degradation, a short bioactive half-life at the target site in vivo, or are ...
Michael Pujari-Palmer, Shiuli Pujari-Palmer, Håkan Engqvist, Marjam Karlsson Ott   +3 more
doaj   +1 more source

The Effect of Rebamipide on Ocular Surface Disorders Induced by Latanoprost and Timolol in Glaucoma Patients

Journal of Ophthalmology, 2015
Purpose. To examine the efficacy of ophthalmic rebamipide suspensions on ocular surface disorders induced by antiglaucoma eye drops. Patients and Methods.
Naoto Tokuda, Yasushi Kitaoka, Akiko Matsuzawa, Junsuke Miyamoto, Shinsuke Sakae, Yasunari Munemasa, Hitoshi Takagi   +6 more
doaj   +1 more source